OMass Therapeutics

top of page

Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBD

CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving...

Company News

Oct 9

OMass Therapeutics CEO Ros Deegan on the company's "whole ecosystem" approach to drug discovery

She describes OMass' platform and rare disease focus.

Company News

May 1, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBD

OMass Therapeutics CEO Ros Deegan on the company's "whole ecosystem" approach to drug discovery

Follow BiotechTV

Sponsors

Sponsor Spotlight